<?xml version="1.0" encoding="UTF-8"?>
<p>Professor Cowman and Dr. Sleebs are also working with Johnson &amp; Johnson, in alignment with the company’s mandate to collaborate broadly in global health R&amp;D, to develop drugs targeting critical 
 <italic>Plasmodium</italic> pathways. BVGH facilitated this collaboration upon learning of the WEHI team’s interest in screening Johnson &amp; Johnson’s Jump-stARter library, a set of 80,000 high-quality compounds representing significant structural and functional diversity. Hit-to-lead optimization is ongoing [
 <xref rid="B28-tropicalmed-04-00053" ref-type="bibr">28</xref>]. 
</p>
